NCT05817435View on ClinicalTrials.gov

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions
Bioequivalence
Interventions
BIOLOGICAL

efgartigimod PH20 SC as a prefilled syringe presentation

efgartigimod PH20 SC as a prefilled syringe presentation

BIOLOGICAL

efgartigimod PH20 SC as a vial + syringe presentation

efgartigimod PH20 SC as a vial + syringe presentation

Trial Locations (2)

68510

Investigator site 0010208, Lincoln

85282

Investigator site 0010209, Tempe

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY